Video

Dr. Slovin on Considerations for Treatment Selection in Nonmetastatic CRPC

Susan F. Slovin, MD, PhD, discusses considerations for treatment selection in nonmetastatic castration-resistant prostate cancer.

Susan F. Slovin, MD, PhD, medical oncologist, associate vice chair, Academic Administration, Department of Medicine, Memorial Sloan Kettering Cancer Center, discusses considerations for treatment selection in nonmetastatic castration-resistant prostate cancer (CRPC).

Several therapies that have demonstrated similar efficacy are available to treat men with nonmetastatic CRPC, Slovin says. Without comparative data, safety should be a key consideration for treatment selection. Additionally, potential sensitivity, allergic reactions, and drug-drug interactions should be carefully reviewed prior to selecting, Slovin says.

Guidelines should also be followed to determine whether a patient is more likely to respond to a particular therapy vs another. In general, however, all available options to treat nonmetastatic CRPC are reasonable choices. Ultimately, treatment selection should be based on physician expertise and individual patient characteristics to optimize therapy, Slovin concludes.

Clinicians referring a patient to MSK can do so by visiting msk.org/refer, emailing referapatient@mskcc.org, or by calling 833-315-2722.
Related Videos
Jonathan Spicer, MD, PhD, FRCS
Daniel DeAngelo, MD, PhD
Marc J. Braunstein, MD, PhD, associate professor, Department of Medicine, co-director, Hematology-Oncology System, New York University (NYU) Grossman Long Island School of Medicine
Douglas W. Sborov, MD, MS, associate professor, Department of Internal Medicine—Division of Hematology and Hematologic Malignancies; director, Hematology Disease Center and Plasma Cell Dyscrasias Program, the University of Utah Huntsman Cancer Institute
Bradley C. Carthon, MD, PhD
David C. Fisher, MD
Alan Tan, MD
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss unmet needs and future research directions in ALK-positive and ROS1-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for lorlatinib in ROS1-positive NSCLC after crizotinib and chemotherapy.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for taletrectinib in ROS1-positive advanced non–small cell lung cancer.